Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Anthracyclines are widely used cancer treatments but can cause cardiac dysfunction.
• Prior research suggests atorvastatin may mitigate this side effect.
• A clinical trial was needed to confirm atorvastatin's cardioprotective effects in cancer patients.

Purpose of the Study:

• To determine if atorvastatin reduces cardiac dysfunction in lymphoma patients undergoing anthracycline chemotherapy.
• To assess the impact of atorvastatin on left ventricular ejection fraction (LVEF) decline.

Main Methods:

• A double-blind, randomized trial involving 300 lymphoma patients receiving anthracycline chemotherapy.
• Participants received either atorvastatin (40 mg/d) or a placebo for 12 months.
• Cardiac function was monitored by measuring LVEF decline over 12 months.

Main Results:

• Atorvastatin significantly reduced the incidence of a ≥10% decline in LVEF to <55% (9% vs. 22%, P=.002).
• The odds of significant LVEF decline were nearly 3 times higher in the placebo group.
• No significant difference in heart failure events was observed between groups.

Conclusions:

• Atorvastatin effectively reduced chemotherapy-induced cardiac dysfunction in lymphoma patients.
• The findings support the use of atorvastatin for patients at high risk of cardiac dysfunction from anthracycline therapy.
• Further research may explore long-term cardiac event rates.